1-3 of 3
Harveen Dhillon Natarajan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia

Vera Hoving, Albertine Donker, Enrikas Vainorius, Harveen Dhillon Natarajan, Jenn Lachey, Simon Cooper, Dorine W. Swinkels, Saskia Schols
Journal: Blood
Blood (2022) 140 (Supplement 1): 2475–2476.
https://doi.org/10.1182/blood-2022-163698
Published: 2022
Journal Articles

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Lynette C.Y. Chee, David M Ross, Shuh Ying Tan, Joel Wight, George Kannourakis, Miranda Ross, Wei Feng, Ying Jiang, Harveen Dhillon Natarajan, Christine Graham, Christopher Rovaldi, Simon Cooper, Jen L. Salstrom
Journal: Blood
Blood (2022) 140 (Supplement 1): 8181–8183.
https://doi.org/10.1182/blood-2022-166578
Published: 2022
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021